Revolution Medicines (NASDAQ:RVMD) Stock Soars on Positive Pancreatic Cancer Drug Trial Results

Font: Financial Modeling Prep  • Apr 13, 2026

• Revolution Medicines (NASDAQ:RVMD) experienced a significant stock surge following positive Phase 3 trial results for its pancreatic cancer drug, daraxonrasib.
• The experimental drug, daraxonrasib, demonstrated a near-doubling of median overall survival for pancreatic cancer patients compared to standard chemotherapy.
• Leading analysts have revised their price targets upwards for Revolution Medicines, reflecting strong confidence in the company's future prospects and potential stock upside.

Revolution Medicines (NASDAQ:RVMD) is a biotechnology company focused on developing new treatments for cancer. The company is gaining significant attention after announcing positive results for one of its experimental drugs. This news has caused its stock price to increase sharply, separating it from a general downturn in the market.

The main driver for this excitement is Revolution Medicines' pancreatic cancer pill, daraxonrasib. The drug successfully completed a Phase 3 trial, a late-stage study to test a treatment's effectiveness. As reported by Invezz, the trial showed it significantly improved patient survival compared to standard chemotherapy treatments, which are the current common practice.

Patients treated with daraxonrasib had a median overall survival of 13.2 months, which is almost double the 6.7 months for those on chemotherapy. The company also states the drug reduces the risk of death by 60%. This positive data has pushed the stock up 69% since the start of the year.

Following these results, financial analysts are updating their views on the stock. An analyst from Oppenheimer raised their price target for Revolution Medicines to $165 from a previous target of $150. At the time of the update, this new target suggested a potential upside of approximately 22.33% from its trading price of $134.88.

Other firms share this positive outlook. As highlighted by SchaeffersResearch.com, analysts at Leerink and Guggenheim also increased their price targets to $147 and $174, respectively. The stock's recent performance includes hitting a new record high of $135.81, with a market capitalization now around $26.53 billion.